The immunotherapy approach used was closely related to tumor type, with the majority of patients receiving anti-CTLA-4 antibodies being treated for melanoma, with similar results observed in the combination (anti-PD-L1/PD-1 and anti-CTLA-4) group. Here, PDCD1 is linked to neoplasm.